Trial NCT01357655

View at ClinicalTrials.gov 
Org. Study IDs: CA180-363
Secondary IDs: 2011-000083-10

Last trial update was posted on 2017-03-14

MeSH Interventions

Dasatinib

MeSH Conditions

Leukemia

Other Conditions


Stopping Reasons

No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.

Limitations And Caveats

No recommended phase 2 dose of the SMO antagonist was determined (in a separate trial). It was decided to discontinue enrollment and end this trial early. The decision was not made due to any new safety signals for dasatinib or the SMO antagonist.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID